Abstract:Introduction: Metabolic remodeling is critically involved in the pathogenesis of cardiac fibrosis. Glycolytic switch provides rapid energy production and biosynthetic intermediates to support proliferation and collagen synthesis of fibroblast. Sirtuin 5 (Sirt5) is a protein lysine de-succinylase that impacts diverse metabolic pathways. Objective: This study aimed to determine the function and mechanism of Sirt5 in cardiac fibroblast activation and cardiac fibrosis. Methods and Results: SIRT5 expression was examined in human and mouse myocardia, and was found to be downregulated in fibrotic myocardial tissues compared to non-fibrotic tissues. In a mouse model of myocardial infarction, Sirt5-knockout (KO) mice showed more severe cardiac fibrosis compared with wild-type mice. The aggravating cardiac fibrosis of Sirt5-KO mice were also found after transverse aortic constriction or angiotensin II plus phenylephrine-infusion. Proliferation and collagen synthesis of cardiac fibroblasts (CFBs) were both significantly enhanced by SIRT5 deficiency after AngII/PE-infusion in vivo and transform growth factor (TGF)-β1-treatment in vitro , but were attenuated by overexpression of Sirt5 in vitro . Moreover, Sirt5 deficiency enhanced a metabolic switch from oxidative phosphorylation to glycolysis in the isolated CFBs, and inhibition of glycolysis diminished the effect of Sirt5 deficiency on CFBs activation. Mechanistically, lysine succinylome analysis identified phosphoenolpyruvate carboxykinase 2 (Pck2), a rate-limiting enzyme in glycolysis pathway, as the protein mostly succinylated after Sirt5 deficiency. Activity of Pck2 was significantly inhibited by Sirt5 deficiency-mediated hypersuccinylation both in vivo and in vitro . K489R mutation of Pck2 diminished its succinylation and the reduction of its enzymatic activity mediated by Sirt5 deficiency, which also blunted the effect of Sirt5 deficiency on CFBs activation. Conclusions: Sirt5 deficiency enhances a metabolic reprogramming from oxidative phosphorylation to glycolysis in CFBs by succinylating Pck2, which promotes CFBs activation and aggravates cardiac fibrosis.

Sirtuin-6 inhibits cardiac fibroblasts differentiation into myofibroblasts via inactivation of nuclear factor κB signaling.

SIRT6 Suppresses Mitochondrial Defects and Cell Death Via the NF-κB Pathway in Myocardial Hypoxia/reoxygenation Induced Injury.

Sirtuin 6 inhibits myofibroblast differentiation via inactivating transforming growth factor-β1/Smad2 and nuclear factor-κB signaling pathways in human fetal lung fibroblasts.

Sirtuin 6 Inhibits Myofibroblast Differentiation Via Inactivating Transforming Growth Factor-Beta 1/Smad2 And Nuclear Factor-Kappa B Signaling Pathways In Human Fetal Lung Fibroblasts

Sirtuin 6 Protects Cardiomyocytes from Hypertrophy in Vitro Via Inhibition of NF‐κB‐dependent Transcriptional Activity

Sirtuin 6 Inhibits Epithelial to Mesenchymal Transition During Idiopathic Pulmonary Fibrosis Via Inactivating TGF-β1/Smad3 Signaling.

SIRT6 Suppresses NFATc4 Expression and Activation in Cardiomyocyte Hypertrophy.

Sirt3 Attenuates Angii-Induced Cardiac Fibrosis by Inhibiting Myofibroblasts Transdifferentiation Via Stat3-Nfatc2 Pathway

SIRT3 Inhibits Ang II-induced Transdifferentiation of Cardiac Fibroblasts Through Β-Catenin/ppar-γ Signaling

Activated Mtorc1-Sirt6 Mediates Myofibroblast Differentiation and Idiopathic Pulmonary Fibrosis

The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun

The Sirtuin 6 Prevents Angiotensin II-mediated Myocardial Fibrosis and Injury by Targeting AMPK-ACE2 Signaling

mTORC1 Signaling Pathway Mediated SIRT6 Overexpression in TGF-β1-Induced Pulmonary Fibrosis

SIRT6 suppresses phenylephrine-induced cardiomyocyte hypertrophy though inhibiting p300.

SIRT6 Protects Against Liver Fibrosis by Negatively Regulating YAP/TAZ

Abstract 9328: Sirt5 Deficiency Promotes Metabolic Reprogramming to Aggravate Cardiac Fibrosis

The Deacetylase Sirtuin 6 Protects Against Kidney Fibrosis by Epigenetically Blocking Β-Catenin Target Gene Expression.

SIRT 6 suppresses phenylephrine-induced cardiomyocyte hypertrophy though inhibiting p 300

SIRT6 Inhibits Inflammatory Response Through Regulation of NRF2 in Vascular Endothelial Cells

Sirtuin 6 attenuates angiotensin II-induced vascular adventitial aging in rat aortae by suppressing the NF-κB pathway

Hypoxia-stimulated Cardiac Fibroblast Production of IL-6 Promotes Myocardial Fibrosis Via the TGF- Β 1 Signaling Pathway